Coherus BioSciences Inc. (CHRS) Receives $39.60 Consensus Price Target from Brokerages
Shares of Coherus BioSciences Inc. (NASDAQ:CHRS) have received a consensus recommendation of “Buy” from the six brokerages that are covering the company. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $39.60.
CHRS has been the subject of a number of recent analyst reports. Credit Suisse Group AG reaffirmed a “buy” rating and set a $38.00 target price on shares of Coherus BioSciences in a report on Wednesday, September 28th. Maxim Group started coverage on Coherus BioSciences in a report on Wednesday, September 7th. They set a “buy” rating and a $43.00 price objective for the company. Barclays PLC reissued a “buy” rating and set a $46.00 price objective on shares of Coherus BioSciences in a report on Thursday, August 11th. Citigroup Inc. started coverage on Coherus BioSciences in a report on Wednesday, July 27th. They set a “buy” rating and a $36.00 price objective for the company. Finally, Zacks Investment Research raised Coherus BioSciences from a “sell” rating to a “hold” rating in a report on Tuesday, July 12th.
Coherus BioSciences (NASDAQ:CHRS) opened at 28.18 on Wednesday. The company’s market cap is $1.22 billion. Coherus BioSciences has a one year low of $12.04 and a one year high of $31.98. The company has a 50-day moving average of $29.11 and a 200-day moving average of $23.25.
Coherus BioSciences (NASDAQ:CHRS) last posted its earnings results on Tuesday, August 9th. The company reported ($1.72) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.32) by $0.40. The company had revenue of $14.07 million for the quarter, compared to analysts’ expectations of $6.87 million. Coherus BioSciences had a negative net margin of 591.61% and a negative return on equity of 1,583.92%. Equities research analysts expect that Coherus BioSciences will post ($6.22) EPS for the current fiscal year.
In other Coherus BioSciences news, insider Peter K. Watler sold 3,991 shares of the company’s stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of $26.13, for a total value of $104,284.83. Following the completion of the sale, the insider now owns 3,991 shares of the company’s stock, valued at $104,284.83. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Peter K. Watler sold 73,741 shares of the company’s stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $25.02, for a total value of $1,844,999.82. Following the completion of the sale, the insider now directly owns 50,000 shares of the company’s stock, valued at approximately $1,251,000. The disclosure for this sale can be found here. 32.88% of the stock is owned by company insiders.
A number of hedge funds have recently modified their holdings of CHRS. BlackRock Inc. raised its stake in shares of Coherus BioSciences by 440.1% in the second quarter. BlackRock Inc. now owns 7,659 shares of the company’s stock valued at $129,000 after buying an additional 6,241 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Coherus BioSciences during the third quarter valued at about $225,000. Bourgeon Capital Management LLC purchased a new stake in shares of Coherus BioSciences during the second quarter valued at about $226,000. Jennison Associates LLC purchased a new stake in shares of Coherus BioSciences during the second quarter valued at about $228,000. Finally, State Board of Administration of Florida Retirement System purchased a new stake in shares of Coherus BioSciences during the second quarter valued at about $241,000. 58.37% of the stock is owned by institutional investors and hedge funds.
Coherus BioSciences Company Profile
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial.
Receive News & Stock Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related stocks with our FREE daily email newsletter.